期刊
GYNECOLOGIC ONCOLOGY
卷 130, 期 3, 页码 518-524出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2013.06.003
关键词
CRAd; Gene therapy; Infectivity-enhanced adenoviral vectors; Ovarian cancer
资金
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
- UAB Comprehensive Cancer Center's Clinical Protocol and Data Management Shared Facility [P30 CA013148]
Objective. The conditionally replicative adenovirus Ad5/3-Delta 24 has a type-3 knob incorporated into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have shown that Ad5/3-Delta 24 achieves significant oncolysis and anti-tumor activity in ovarian cancer models. The purpose of this study was to evaluate in a phase I trial the feasibility and safety of intraperitoneal (IP) Ad5/3-Delta 24 in recurrent ovarian cancer patients. Methods. Eligible patients were treated with IP Ad5/3-Delta 24 for 3 consecutive days in one of three dose cohorts ranging 1 x 10(10)-1 x 10(12) vp. Toxicity was assessed utilizing CfC grading and efficacy with RECIST. Ascites, serum, and other samples were obtained to evaluate gene transfer, generation of wildtype virus, viral shedding, and antibody response. Results. Nine of 10 patients completed treatment per protocol. A total of 15 vector-related adverse events were experienced in 5 patients. These events included fever or chills, nausea, fatigue, and myalgia. All were grades 1-2 in nature, transient, and medically managed. Of the 8 treated patients evaluable for response, six patients had stable disease and 2 patients had progressive disease. Three patients had decreased, FA-125 from pretreatment levels one month after treatment Ancillary biologic studies indicated Ad5/3-Delta 24 replication in patients in the higher dose cohorts. All patients experienced an anti-adenoviral neutralizing antibody, effect. Conclusions. This study suggests the feasibility and safety of a serotype chimeric infectivity-enhanced CRAd, Ad5/3-Delta 24, as a potential therapeutic option for recurrent ovarian cancer patients. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据